首页> 美国卫生研究院文献>Immunology >Asymmetric non-precipitating antibodies in commercial hyperimmune gamma-globulin for therapeutic use.
【2h】

Asymmetric non-precipitating antibodies in commercial hyperimmune gamma-globulin for therapeutic use.

机译:用于治疗用途的商业超免疫γ-球蛋白中的不对称非沉淀抗体。

代理获取
本网站仅为用户提供外文OA文献查询和代理获取服务,本网站没有原文。下单后我们将采用程序或人工为您竭诚获取高质量的原文,但由于OA文献来源多样且变更频繁,仍可能出现获取不到、文献不完整或与标题不符等情况,如果获取不到我们将提供退款服务。请知悉。

摘要

The presence of asymmetric (non-precipitating or co-precipitating) antibodies has been studied in three commercial preparations of antitetanus gamma-globulin. It was found that 27% of the specific antibodies are of asymmetric type, a value two to three times higher than that found in normal IgG. In toxicity tests in mice with tetanus toxin, the asymmetric antibodies were 2.7 times less effective than the symmetric ones. It is concluded that the protection capacity of the tetanus gamma-globulin preparations is dependent on the ratio of symmetric to asymmetric antibodies. The high content of asymmetric antibodies is probably due to the fact that immunization is performed with the antigen in a particulate form.
机译:在三种抗破伤风γ球蛋白的商业制剂中,已经研究了不对称(非沉淀或共沉淀)抗体的存在。发现27%的特异性抗体是不对称类型的,其值是正常IgG中发现的值的两到三倍。在破伤风毒素小鼠的毒性试验中,不对称抗体的有效性比对称抗体低2.7倍。结论是,破伤风γ-球蛋白制剂的保护能力取决于对称抗体与不对称抗体的比例。高含量的不对称抗体可能是由于使用颗粒形式的抗原进行免疫。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
代理获取

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号